Table 4 Comparison of adverse effects between the weekly bevacizumab group and the monthly bevacizumab group
Adverse effects | Group A (n = 44) | Group B (n = 33) | p-Value | ||
|---|---|---|---|---|---|
Grade 1/2 | Grade 3/4 | Grade 1/2 | Grade 3/4 | ||
Anemia | 41 | 2 | 20 | 12 | < 0.01 |
Neutropenia | 22 | 10 | 12 | 18 | < 0.01 |
Thrombocytopenia | 29 | 2 | 14 | 1 | 0.99 |
Febrile neutropenia | 0 | 0 | 0 | 0 | 0.99 |
aspartate aminotransferase level increased | 0 | 1 | 4 | 1 | 0.99 |
alanine aminotransferase level increased | 2 | 0 | 2 | 0 | 0.99 |
Fatigue | 37 | 0 | 11 | 0 | 0.99 |
Stomatitis | 11 | 0 | 0 | 0 | 0.99 |
Nausea | 32 | 1 | 10 | 2 | 0.57 |
Hypertension | 5 | 1 | 4 | 11 | < 0.01 |
Thromboembolic event | 1 | 0 | 2 | 6 | < 0.01 |
Proteinuria | 3 | 0 | 9 | 1 | 0.43 |
Gastrointestinal perforation | 0 | 0 | 0 | 2 | 0.57 |
Intestinal obstruction | 0 | 0 | 4 | 6 | < 0.01 |
Cardiac disorder | 0 | 0 | 1 | 0 | 0.99 |
Hand and foot syndrome | 10 | 0 | 0 | 0 | 0.99 |
Constipation | 15 | 0 | 2 | 0 | 0.99 |
Diarrhea | 3 | 0 | 1 | 1 | 0.43 |
Taste disorder | 3 | 0 | 1 | 0 | 0.99 |